Nutriband Inc.

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%
HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

At a Glance

Live Snapshot
Market Cap$50.45M
EPS-0.9900
P/E Ratio-4.19
Earnings Date04/27/2026

ntrb

Net Cash Provided by Financing Activities

Last Annual Value

8.54M

3-Year CAGR

4%

5-Year CAGR

82%

10-Year CAGR

211%

Nutriband Inc.

Nutriband Inc. Competitors Analysis of Net Cash Provided by Financing Activities

NTRB · NASDAQ
CompanyNet Cash Provided by Financing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
8.54M
59.9%2.3%47.5% 
-336.00K
N/AN/AN/A
93.56M
N/A-13.0%N/A
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
-10.25M
N/AN/AN/A
-749.00K
N/AN/AN/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
75.25M
583.2%-20.9%N/A
28.45M
31.0%-7.4%N/A
14.89M
N/A-19.3%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
4.24M
-34.7%-49.2%N/A
IMA logo
ImageneBio Inc
NASDAQ:IMA
135.47M
21.3%0.6%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
65.58M
298.9%8.9%18.1%
Nutriband Inc.

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

Intrinsic Value
Current Price: $4.15